Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Baraclude

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

- PMLiVE

Another lost decade for research?

What does the patent landscape look like for antibiotics, vaccines and orphan drugs?

EISAI

Eisai expands in China with generics company acquisition

BuysLiaoning TianYi Biological Pharmaceutical

- PMLiVE

BMS’ Empliciti approved by FDA for multiple myeloma

Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone

Bristol-Myers Squibb (BMS) building

Bump in the road slows momentum for BMS’ Opdivo

FDAturns down the cancer treatment for a form of melanoma

Teva Pharma logo

Teva buys into Heptares oral CGRP programme for migraine

Signs$410m alliance for early-stage candidates in potentially-lucrative drug class

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

Teva Pharma logo

TEVA’s tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

Teva Pharma logo

TEVA buys Mexico’s RIMSA for $2.3bn

Follows acquisition ofAllergan’s generic drugs business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links